Moscow: Russia’s Sputnik V vaccine is 91.6 percent effective against symptomatic Covid-19, according to results published in The Lancet.
Sputnik V — named after the Soviet-era satellite — was approved in Russia months before results from its final-stage clinical trials were published, leading to scepticism from experts.
But the new analysis of data from 20,000 participants in Phase 3 trials suggests that the two-dose vaccination offers more than 90 percent efficacy against symptomatic Covid-19.
“The development of the Sputnik V vaccine has been criticised for unseemly haste, corner cutting, and an absence of transparency,” said an independent Lancet commentary by Ian Jones of the University of Reading and Polly Roy of the London School of Hygiene and Tropical Medicine.
“But the outcome reported here is clear and the scientific principle of vaccination is demonstrated, which means another vaccine can now join the fight to reduce the incidence of Covid-19.”
The results suggest Sputnik V is among the top performing vaccines, along with the Pfizer/BioNTech and Moderna jabs that also reported more than 90 percent efficacy.
Sputnik V uses two different disarmed strains of the adenovirus, a virus that causes the common cold, as vectors to deliver the vaccine dose.
Several countries around the world have already registered Sputnik V, according to the Russian Direct Investment Fund which helped develop the vaccine, including Belarus, Venezuela, Bolivia and Algeria.
The vaccine has the advantage of being able to be stored at normal refrigerator temperatures instead of the conditions far below freezing required for some other vaccines.
